Information Provided By:
Fly News Breaks for July 21, 2017
RVNC
Jul 21, 2017 | 08:23 EDT
Cantor Fitzgerald analyst Louise Chen started Revance Therapeutics with an Overweight rating and $50 price target. The analyst sees positive news flow for the company's key programs in development driving both estimates and the shares higher. Chen expect Revance to report positive results before the end of the year for its Phase 3 pivotal trials for glabellar lines and Phase 2 results for its new indication, plantar fasciitis.
News For RVNC From the Last 2 Days
There are no results for your query RVNC
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.